Small Molecules

22 Mar 2018 Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
22 Mar 2018 Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
21 Mar 2018 First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy
21 Mar 2018 Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
21 Mar 2018 Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
21 Mar 2018 Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
20 Mar 2018 Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
20 Mar 2018 U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
19 Mar 2018 Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB
19 Mar 2018 Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair
19 Mar 2018 Forendo Pharma receives €3 million loan from Business Finland to develop novel treatments for endometriosis
19 Mar 2018 eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
16 Mar 2018 Q Biomed Inc. announces FDA filing for approval of a new manufacturing facility for non-opioid Strontium Chloride SR89 Injection USP for relief of cancer bone pain
16 Mar 2018 Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome
16 Mar 2018 AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
15 Mar 2018 Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism
15 Mar 2018 Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
15 Mar 2018 Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
15 Mar 2018 Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
15 Mar 2018 BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
15 Mar 2018 Auris Medical Provides Business Update
14 Mar 2018 Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I
13 Mar 2018 AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
13 Mar 2018 Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
13 Mar 2018 Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing